Objectives: Carotid endarterectomy (CEA) is supported by level 1 evidence as the standard treatment of severe carotid stenosis in both symptomatic and asymptomatic patients. As interventional techniques are emerging for treatment of this disease, this study was undertaken to provide a contemporary surgical standard for comparison to carotid stenting. Patients and methods: During the interval 1989 to 1999, 2236 isolated CEAs were performed on 1897 patients (62% male, 36% symptomatic, 4.6% reoperative procedures). Study endpoints included perioperative events, patient survival, late incidence of stroke, anatomic durability of CEA, and resource utilization changes during the study. Variables associated with complications, long-term and stroke free survival, restenosis, and resource utilization were analyzed by univariate and multivariate analysis. Results: Perioperative complications occurred in 5.5% of CEA procedures, including any stroke/death (1.4%), neck hematoma (1.7%), cardiac complications (0.5%), and cranial nerve injury (0.4%). Actuarial survival at 5 and 10 years was 72.4% (95% confidence interval ͓CI͔ 69.3-73.5) and 44.7% (95% CI 41.7-47.9) respectively, with coronary artery disease (P Ͻ 0.0018), chronic obstructive pulmonary disease (P Ͻ 0.00018) and diabetes mellitus (P Ͻ 0.0011) correlating with decreased longevity. The age-and sex-adjusted incidence of any stroke during follow-up was reduced by 22% (upper 0.35, lower 0.08) of predicted with the patient classification of hyperlipidemia (P Ͻ 0.0045) as the only protective factor. Analysis of CEA anatomic durability during a median follow-up period of 5.9 years identified a 7.7% failure rate (severe restenosis/occlusion, 4.5%; or reoperative CEA, 3.2%) with elevated serum cholesterol (P Ͻ 0.017) correlating with early restenosis. Resource utilization diminished (first versus last 2-year interval periods) for average hospital length of stay from 10.3 Ϯ 1.5 days to 4.3 Ϯ 0.7 days (P Ͻ 0.01) and preoperative contrast angiography from 87% Ϯ 1.4% to 10.3% Ϯ 4%. Conclusions: These data delineate the safety, durability, and effectiveness in long-term stroke prevention of CEA. They provide a standard to which emerging catheter-based therapies for carotid stenosis should be compared.
T he level 1 evidence that supports carotid endarterectomy (CEA) as the standard treatment of severe asymptomatic and symptomatic carotid stenosis include the North American Symptomatic Carotid Endarterectomy Trial (NASCET), 1 the European Carotid Surgery Trial (ECST), 2 and the Asymptomatic Carotid Atherosclerosis Study (ACAS). 3 These large, randomized, prospective trials have demonstrated significant reduction of stroke and death when comparing CEA to best medical treatment. These studies have confirmed the natural history of carotid stenosis as a significant contributor to stroke and have also underlined the importance of perioperative surgical outcome as the major determinant of benefit with CEA in specific patients. Although a perioperative risk (stroke/death) of less than 3% has been accepted as the determinant for a favorable result for carotid surgery, 4 there remains controversy as to which specific clinical or anatomic variables are associated with inferior results after CEA. [5] [6] [7] [8] [9] [10] [11] The definition of such a "high-risk" subgroup of patients would logically constitute a patient cohort in whom an alternative therapeutic approach, such as carotid artery angioplasty and stenting (CAS), could potentially become a preferred alternative to CEA. 8, [12] [13] [14] [15] [16] While a frequently cited, large, retrospective study has purported to define such a subgroup, 17 a variety of subsequent reports have noted equivalent results after CEA even in patient groups stratified as "high risk" by significant comorbities. 7,11,18 -20 With the application of percutaneous interventional therapy to carotid stenosis, multiple observational clinical series have been published advocating this less invasive technique as comparable treatment to CEA. 12, 14, [21] [22] [23] [24] In addition, adjuvant cerebral protection devices to prevent cerebral embolization during CAS have been developed, and their application has provided a major positive impact on the safety of CAS. 22, 25 With this refinement in CAS technique, several prospective, randomized trials have emerged to compare CAS with CEA. 26 -28 One such study, the as yet unpublished SAPPHIRE trial, 29 has specifically targeted the "high-risk" patient with cardiac comorbidities for randomization between CAS or CEA. This study has suggested that the safety and efficacy of this percutaneous intervention is comparable or better than that of CEA in this patient population. 30 As clinical trials investigating the role of CAS interventional therapy for the treatment of severe carotid stenosis become available, this study was undertaken for the purpose of examining the perioperative and late outcomes of a large contemporary surgical series of CEA.
METHODS

Patient Selection
The computerized databases of the Massachusetts General Hospital (retrospective) and Vascular Surgery Registry and operative logs (prospective) were cross-referenced to identify 1897 patients who underwent 2236 consecutive CEA procedures between January 1989 through December 1999 by surgeons in the Division of Vascular Surgery. Only isolated CEA operations were included in the study; those performed in conjunction with another surgical procedures such as cardiac surgery, aortic arch branch reconstruction, or carotid bypass were excluded from analysis.
Patient demographics, indications, imaging studies, operative details, and clinical course were recorded from hospital and office records. The determination of clinical criteria was made by review of data during the year of the CEA, and their definitions are hypertension: taking antihypertensive medication, consistent BP Ͼ150 systolic or Ͼ90 diastolic; diabetes mellitus: receiving insulin or oral hypoglycemic medication; coronary artery disease: history of myocardial infarction, congestive heart failure, coronary artery bypass graft or intervention, symptoms of angina, or identification of a positive stress test; chronic obstructive pulmonary disease: routine use of inhalers or symptoms of lifestyle-limiting dyspnea, and hyperlipidemia (1Lipid), use of cholesterollowering medication (Ͼ80% of patients), or having a fasting cholesterol Ͼ200. In addition, when long-term follow-up outcomes were not available, direct telephone contact with the patient or family was performed (n ϭ 268, 14.1%). For those patients who could not be reached and lacked recent clinical data, the date and causes of death were requested and procured from the National Death Index in Bethesda, Maryland. The primary or underlying diagnostic codes provided by the National Death Index for stroke (ICD-9 430 -438, and I690 -I699), which are the standards used in population-based studies 31 to calculate the stroke incidence in the United States, were used as evidence for stroke during patient follow-up.
The primary end point of the study included perioperative stroke and death rate and patient long-term and strokefree survival. Stroke and transient ischemic attack were defined in accordance with the reporting standards of the ad hoc committee on cerebrovascular reporting of the Society of Vascular Surgery and The North American Chapter of The International Society of Cardiovascular Surgery. 32 Stroke was defined as a neurologic deficit that persists beyond 24 hours, or, when obtained selectively, the identification of new findings consistent with cerebral infarction on brain imaging. Transient ischemic attacks were defined as focal neurologic findings that resolved within 3 hours.
Since the primary objective of CEA surgery is stroke prevention, stroke-free survival was investigated starting from the time of surgery. The stroke end point was assigned to all patients who suffered a stroke either in the postoperative period or during the follow-up. The data from a US population-based study, 31 updated in 1995, that identified the incidence of stroke was matched for age and sex to our study population to analyze the standard incidence ratio of stroke in our cohort of patients undergoing CEA.
Secondary end points in the study included other 30day perioperative complications, anatomic failure of the CEA, and resource utilization during the course of the study. The definition of the perioperative complications include clinically evident cranial nerve injury identified at 24 hours; surgical site bleeding requiring extended hospital observation or operative exploration; cardiac complications: development of myocardial infarction by EKG or selectively obtained serum cardiac enzymes, congestive heart failure, or unstable angina; pulmonary: requiring reintubation or developing pneumonia; infection: surgical site cellulitis requiring antibiotics; renal failure: elevation of creatinine Ͼ2 ϫ baseline; hyperperfusion injury: syndrome of postoperative severe ipsilateral headache, difficult to control hypertension, and cerebral edema on CT scan without evidence of cerebral infarction.
Anatomic failure, the converse of anatomic durability, of the CEA procedure was defined as one requiring a reoperation or resulting in internal carotid occlusion or severe (Ͼ70% diameter) restenosis by Duplex ultrasound vascular laboratory criteria based on peak systolic velocity. Length of stay and postoperative days (calendar days during hospitalization) were recorded for all CEA patients in the study, including those admitted or discharged through other services.
The protocols of this study were independently reviewed and approved by the institutional human study committee. In addition, the review board of the National Death Index in Bethesda, Maryland, approved the protocol for release of the patient data.
Procedures
CEA was performed in symptomatic and asymptomatic patients with severe carotid artery stenosis (a Ն70% stenosis involving the carotid artery bifurcation) by carotid noninvasive evaluation. 33 Symptomatic patients, irrespective of comorbidities, and asymptomatic patients without evident limitations of life expectancy and deemed to be good operative candidates have always been offered CEA at our institution. Further evaluation of the anatomic detail with catheter-based contrast angiography, magnetic resonance angiography, or computed axial tomography with reconstructions was at the surgeon's discretion. Preoperative cardiac risk was clinically assessed, and cardiac risk stratification testing undertaken as appropriate.
Operative procedures were performed either under general anesthesia with electroencephalographic monitoring to identify significant cerebral ischemia after clamping the carotid or under regional anesthesia (3%) with clinical neurologic monitoring. Symptomatic patients were kept on heparin during the preoperative period. Prior to carotid clamping all patients were fully anticoagulated with heparin. During the period of the study, all CEAs were performed by longitudinal arteriotomy through the common and internal carotid arteries; the eversion endarterectomy technique of the internal carotid artery was not performed. Selective carotid shunting was used with EEG or clinical evidence of decreased cerebral blood flow; however, the practice of using a temporary shunt in patients with a recent stroke was also commonly employed. The use of a venous or prosthetic patch for the closure of the carotid artery was undertaken during reoperative procedures, in patients with small diameter arteries, and in circumstances when the endarterectomy plane was technically difficult. Intraoperative assessment of the reconstruction was undertaken by a continuous-wave Doppler ultrasound, and intraoperative angiography was only selectively employed. Anticoagulation was generally not reversed with protamine. Patients were given perioperative aspirin, and on occasion low-molecular-weight dextran was administered at the surgeon's discretion.
The perioperative care evolved during the course of the study due to the implementation of specific clinical pathways. In the early years, it was common to admit the patients for angiography, delay their surgery for a day thereafter, and have the patients recover in an intensive care unit or overnight recovery room. In the later years of the study, the majority of patients were observed for 4 hours in the postanesthesia care unit before being transferred to the floor and discharged the next morning when appropriate. Postoperative outpatient follow-up was generally within 6 weeks, with carotid duplex ultrasound of the operative site and continued follow-up at least to 2 years, unless evidence of carotid restenosis developed.
Data Analysis
Postoperative survival was computed using the Kaplan-Meier estimate. Odds ratios for factors effecting restenosis were computed using the GEE method, clustering on patients. Dichotomous factors affecting the dichotomous outcome postoperative stroke were assessed using a Fisher exact test. The effect of continuous variables (cholesterol) was assessed using logistic regression. Univariate and multivariate models for postoperative survival and anatomic durability were assessed using proportional hazards models. Resource utilization during the period of the study was analyzed by ANOVA, and differences in death/complications during the early and late periods of the study was compared with a student's t test. Data were presented as averages Ϯ SD, and a P value of less than 0.05 was considered statistically significant.
RESULTS
Perioperative Results
There were 2236 CEA operations performed on 1897 patients during the study period. This primarily male (62%) cohort of patients averaging 70 years of age included many of the comorbidities in patients with arteriosclerosis (Table 1) . Thirty-six percent of CEA were for symptomatic disease, 7.1% of CEA presented with an ipsilateral stroke, and 4.6% required a reoperative CEA ( Table 2) .
There was a 5.5% complication rate identified in the 30-day postoperative period (Table 3 ). Of the 13 (0.6%) deaths, 6 involved strokes, with 1 contralateral intracranial hemorrhage and 1 bilateral cerebral infarction. The remaining perioperative deaths included 3 cardiac, 2 mesenteric infarctions, and 2 multisystem failures. There were 18 postoperative strokes (0.8%), 14 affected only the ipsilateral hemisphere, but there were 2 isolated to the contralateral hemisphere, 1 bilateral hemisphere, and 1 stroke isolated to the posterior circulation. This resulted in a combined stroke/ death rate of 1.4%. Six patients (0.3%) developed transient neurologic findings, which resolved within 3 hours. In this group of patients imaging evaluation with clinical examination follow-up and brain imaging failed to reveal a neurologic deficit or evidence of cerebral infarction. Cranial nerve palsy was identified in 10 patients with the affected nerves: VII, 2; X, 5; XII, 3; only 1 was identified in the reoperative CEA group. Postoperative bleeding or hematoma, the most common complication at 1.7%, was most commonly seen in patients requiring warfarin anticoagulation. Cardiac complications occurred in 11 patients (0.5%), while of the 9 (0.4%) pulmonary complications, 6 were postoperative pneumonia and 2 patients developed respiratory failure requiring assisted ventilation. Of the 5 (0.2%) infection complications, 1 was an infection from the vein patch harvest site in the leg; the remainder was from the neck incision. The incidence of acute renal failure was seen in 3 patients (0.13%); all had previously undergone preoperative contrast angiography. Further analysis of these complications did not demonstrate a significantly higher incidence of complications in either reoperative CEA, cases having a prior contralateral operation, or in association with a specific clinical variable. However, combining all deaths and complications, their incidence in the last 5 years of the study (4.8 Ϯ 1.0%) was significantly lower than the previous 5 years (7.5 Ϯ 1.3%; P Ͻ 0.006).
Survival
The mean follow-up period was 5.9 years (range 0.1 to 14.6). Follow-up data for survival were available in 99.6% of patients. The Kaplan-Meyer curve for survival appeared relatively uniform (Fig. 1 ) demonstrates a 1-, 5-, and 10-year survival of 93.0%, 72.4%, and 44.7%, respectively. Variables impacting patient longevity, analyzed by multivariate analysis, are displayed in Table 4 .
There were 10,978 patient-years of CEA patients examined in this study, which, based on sex and age matching, (Table 5 ).
Anatomic Failure
Anatomic failure, with follow-up data available for 81% of the CEA, was identified by 58 (3.2%) reoperative CEA procedures, and carotid noninvasive testing revealed 18(1.0%) internal carotid occlusions and 64 (3.5%) severe Ն75% stenoses, for a total anatomic failure rate of 7.7%. During the follow-up period of this subgroup, 1 patient in the reoperative group and 4 patients in the nonoperative group developed a stroke. In the nonoperative group, 3 were identified in follow-up, and 1 had a stroke during an attempted carotid intervention at another institution. Multivariate analysis of the possible factors contributing to the development of restenosis revealed only elevated serum cholesterol value (P Ͻ 0.017) as a significant causative factor (Table 6 ).
Resource Utilization
The length of stay in the first 2 years of the study (10.3 Ϯ 1.5) compared with the last 2 years of the study (4.3 Ϯ 0.7, P Ͻ 0.01) decreased by 58% (Fig. 2) . Postoperative days, which is more reflective of surgical practice, also decreased between the first (6.5 Ϯ 1.4) and last (2.5 Ϯ 0.5) 2 years by 62% (P ϭ Ͻ.01).
Another major change in resource utilization during the study period includes preoperative imaging techniques (Fig.  3 ). The first 2 years, 87% Ϯ 1.4% utilization of contrast angiography decreased to 10% Ϯ 4% during the final 2 years of the study. The use of other axial (magnetic resonance angiography, computed tomographic angiography) imaging with reconstruction views increased through 1995, when use of all other preoperative imaging declined as carotid noninvasive studies was more accepted as the sole criterion for CEA in routine patients.
The method of surgical reconstruction of the carotid artery also changed. While only 39% of arteries underwent patch closure of the carotid artery during the first 2 years of the study, 72% underwent patch reconstruction in the last 2 years. Of interest, while vein patches (82%/first 2 years) were primarily used in the beginning part of the study, they comprised less than 3% of carotid patches during the last 2 years, being replaced with Dacron patches (95%/last 2years). The use or type of patch had no impact on perioperative complication rates.
DISCUSSION
Multiple studies have consistently demonstrated that CEA is a safe and durable procedure that is effective in the prevention of stroke in patients with both symptomatic and asymptomatic severe carotid stenosis. 1-3,11,18,34 -36 These findings have been underscored in our study of a contemporary cohort of patients undergoing CEA. It needs to be emphasized that the randomized, prospective studies have provided practice guidelines for CEA with the predicate that the morbidity and mortality rate be less than the natural history of the disease. 4 Although lacking the strengths of prospective and randomized trials, large institution-based studies can provide additional valuable information by incorporating patients into the series that may not have met specific inclusion criteria for the designated trial, while adjusting the standard of best medical care over the duration of the study. Specific modifications in clinical practice can clearly translate into improved outcomes, as illustrated by the significant 36% reduction in morbidity and mortality identified in the last 5 years of this study compared with the previous 5 years. This reduction can be linked to the virtual elimination of routine preoperative contrast angiography over the course of our study, resulting in the avoidance of the significant local and systemic complications known to occasionally result from such invasive diagnostic procedures. For example, in the ACAS study, 3 preoperative angiograms contributed an incidence of 0.6% strokes; a cohort of patients likely missed in our study, since patient capture was at the time of CEA and not at intention to treat. Other more subtle changes in clinical management relating to anesthetic, medical, or monitoring improvements in patient management such as the increased use of ␤-blockers in the perioperative period 9 can also improve outcomes reflected by the low 11 (0.5%) cardiac complications and 3 cardiac deaths (0.13%) in our and other contemporary studies. 11, 18, 34, 36 However, routine examination of serum markers for cardiac injury was not employed except in high-risk symptomatic patients or patients with postoperative EKG changes, and, therefore, minor cardiac complications could have been missed. Two surgical-site complications in this study included bleeding and cranial nerve injury. Significant hematomas were the most common complication in our study and reflected an aggressive anticoagulation stance. Indeed, preoperative antiplatelet therapy has been the standard practice for the majority of surgeons who treat carotid stenosis and has recently been identified as an important factor in the prevention of perioperative neurologic events despite the increased incidence of bleeding complications. 37 In addition, the reluctance of employing protamine reversal of the heparin results from its possible association with perioperative stroke. 38 The identification of cranial nerve injury was low in our study, most were transient, and only 1 occurred in a reoperative CEA. Reports with careful postoperative otolaryngologic evaluation, that includes assessment of vocal cord mobility, suggest that the incidence of cranial nerve injury can be as high as 10%, but most of these are reported as mild and rarely permanent. 39, 40 Our data substantiate the rarity of clinically significant cranial nerve dysfunction as a complication of primary or reoperative CEA and, while in conflict with other reports, 41 refutes the argument that fear of such injury should constitute an argument of CAS versus redo CEA in cases of recurrent carotid stenosis.
Our results question the hypothesis that "high-risk" patients constitute a subgroup where CAS might be preferred to CEA. Such patients have been defined either by comorbid conditions 17 (severe coronary disease, chronic obstructive pulmonary disease, renal disease or advanced age) or hostile surgical field 8 (previously operated neck, radiation therapy, a very high carotid bifurcation, or other anticipated technical difficulties). Many patients with these characteristics, as being nonreflective of the general population, would be excluded from the major randomized trials. Logic would dictate that patients in either of those subgroups would have inferior results to CEA and thus be ideal for the less invasive CAS therapy. This concept of a "high-risk" cohort that would be more suitable for CAS has been supported by a retrospective study 17 of CEA that reported a higher (7.9%) postoperative stroke/death rate for "high-risk" cases compared with 2% incidence in the non-high-risk cohort, for a combined incidence of 3.2%. Although the combined results are equivalent to the randomized studies 1-3 and guidelines, 4 this study should not be used for defining such a cohort of patients because of its inclusion of patients undergoing combined CEA and cardiac surgery. In fact, over 67% of the patients in the "high-risk" group underwent combined CEA/cardiac surgery. Since the combined CEA/cardiac surgery procedures are known to have a higher death and complication rate, 42 it would not be appropriate to include such a cohort of patients when trying to define a "high-risk" group for isolated CEA.
Other contemporary studies which focused on isolated CEA have failed to duplicate these observations, reporting perioperative stroke/death rates of 1.9% 11 and 1.6% 34 unaffected by patient comorbitities or hostile surgical field, while another study with a 1.1% stroke/death rate 7 proposed the "high-risk" patient may be a small group determined by adverse anatomic factors.
There have been CAS patient series 25 and registry reports 22 by experienced interventional therapists which have reported periprocedural stroke/death incidence of 7.4% and 4.8%. However, even these series demonstrated improvement in later years (7.1% to 3.1%) or with the introduction of distal protection devices in the internal carotid artery (5.3% to 2.2%), emphasizing the importance of operator experience, protocol development, and technological advances in patient outcome. There have also been 2 recent prospective trials comparing CEA and CAS, the CAVATAS 26 and the CA-RESS 27 trials. Both trials have reported finding equivalent periprocedural incidence of stroke/death between CEA and CAS: CAVATAS 10.0% versus 9.9% and CARESS 3% versus 2%. However, despite equivalent risk factors between patients in the CAVATAS and other trials, serious concerns have been raised about the very high periprocedural stroke 
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Carotid Endarterectomy and death rate in both arms of the CAVATAS study. Of particular concern was that all 7 deaths in the CAS group were from fatal strokes, while only 1 was in the CEA group. The disproportionately high neurologic complications in the CAS arm with their technical features (few stents and no distal protection) and the acknowledged high discordant surgical complications compared with prior trials 1-3 make the CAVATAS trial results of questionable relevance to continued practice. The SAPPHIRE trial, presented at the American Heart Association, 30 is a prospective, randomized study at 29 US centers comparing CEA and CAS with the use of cerebral protection in "high-risk patients": defined as having congestive heart failure, ejection fraction Ͻ30%, recent myocardial infarction, or unstable angina. There were 307 patients randomized into the study with a CAS procedural success rate (Ͻ30% residual stenosis) of 91.2%. The 30-day major adverse event rate (death, stroke, or myocardial infarction) demonstrated a significant difference between CAS and CEA (5.8% and 12.6%; P Ͻ 0.047). Only combining all 3 complications attained this difference, which could be explained by non Q-wave myocardial infarction in the CEA patients. There were also 416 patients deemed inappropriate for either CEA or CAS and could not be randomized but were entered into a registry and treated by CAS (409) or by CEA (7), with equivalent results to the study patients. The results of our present study compare more favorably to the results of the surgical arm of the SAPPHIRE trial. While arguments could be made about the merits of prospective versus retrospective studies, the differences in criteria for identification of periprocedural myocardial infarction, and patient selection differences between these 2 studies, the degree of discordance (1.9% versus 12.6%) suggests the differences are genuine.
Late survival of our patient population (70% at 5 years) is similar to previously published series. 11, 18, 43 However, the VA Cooperative Trial had a much lower longevity of 63% at 4 years. 44 This difference was primarily attributed to several factors: high rates of coronary artery disease, a male population, and over 90% were smokers at the time of entry to the trial. Typical of reports of patients undergoing interventions for vascular disease, our study identified a high proportion of patients (36%) who succumbed primarily from cardiac causes which, with COPD and diabetes, were found to have a significant negative impact on survival. However, by multivariate analysis in our study, there was an association for improved survival of patients classified as 1Lipids. During the course of the study, over 80% of this patient cohort were prescribed cholesterol-lowering drugs, and these medications are known to prolong survival in patients with coronary disease. 45 Since there is an association of carotid and coronary artery disease 46 and over 55% of patients in the current study had coronary artery disease, it would seem logical that this observed prolonged survival of patients classified as 1Lipids can be attributed to the medical therapy, rather than their disease process. This is the first report to identify this association with an improved late survival for patients after CEA.
The current study adds to the extensive data of CEA on long-term stroke prevention. Since CEA can only prevent stroke attributed to large artery territory, it is difficult to identify the specific contribution of carotid artery disease to stroke. 31 Therefore, the observed 22% risk reduction in this study was significant. Univariate analysis identified the subgroup of patients classified as 1Lipid to have a protective role for stroke-free survival. In fact, cholesterol-lowering drugs have also been described as reducing the incidence of stroke, 47 which may reflect the low incidence of strokes identified in the follow-up period.
In our study, anatomic failure was identified in 7.7% of CEA during the follow-up period. Approximately half underwent reoperative CEA, and 13% were totally occluded, and the remaining had severe stenosis by carotid noninvasive criteria. Although our reported restenosis after CEA is comparable to the literature between 0.1% and 7.9%, 18, 43 there are discrepancies of vascular laboratory criteria and different follow-up periods. In contrast, the majority of the studies reporting CAS restenosis 22, 25, 48 had shorter follow-up of 1-2 years, demonstrating rates of restenosis in the 4% to 14% range.
The reported clinical variables in CAS that are predictive of restenosis include female gender, age, residual stenosis, and multiple stent use. 25 There are some similarities with these etiologic factors and those reported to contribute to CEA restenosis, including female gender and patch use 18, 43 ; however, the only significant clinical variable identified in our study was elevated serum cholesterol. Although the role of elevated lipids is well established in coronary restenosis, 49 there have been only a few studies investigating elevated lipids and CEA failure, but they have not been conclusive. 50, 51 Resource utilization changes have occurred throughout the country by the institution of clinical pathways to identify a standard of care, streamline and facilitate the administration of resources, and contain costs. 52 Well-recognized and publicized trends in the care of CEA patients are reflected in our study with decreased hospital days, while the virtual elimination of contrast angiography as a preoperative imaging modality has the dual effect of decreasing morbidity and resource utilization. Cost of care comparisons between CEA and CAS has reported a 20% procedural savings for CEA over CAS, which increased as differences in outcome were considered in a financial model. 53 However, with a changing market and technology evolution, a prospective comparison would be the optimal method for comparison between CAS and CEA.
Recent studies have outlined the need for procedural excellence, institutional competency, and quality control. 54 CEA was one of the operative procedures listed in this initiative for the identification of optimal care, the success of which can be based in part on experience and volume. [55] [56] [57] With its known natural history, success for CEA has been defined primarily by obtaining a low periprocedural morbidity and mortality. 4 Thus, reason would dictate that prospective randomized trials in the United States evaluating CEA and CAS should use centers that meet the criteria of excellence in care for both CEA and CAS.
The data presented herein reiterate that CEA is a safe, durable, and effective therapy for patients with clinically significant carotid disease. As data emerge, it is clear that CAS will have a role in the treatment of carotid stenosis. The ultimate application of this modality will be defined by emerging and future comparative studies between CAS and CEA.
DR. JOHN E. CONNOLLY (IRVINE, CALIFORNIA): This is a very interesting paper indicating excellent results which one would expect from MGH surgeons and will probably be better than those of C-stenting results. On this May 20th, a 50th celebration of Eastcott and Rob's first case will take place at St. Mary's in London, which I'm looking forward to participating in.
It's been 40 years since my first case and I think I've learned a few lessons that I would like to mention. In 1972 I had a couple of patients whom the anesthesiologists refused to put patient to sleep. I thought about the ease of femoral embolectomy under local, so said to an anesthesia colleague, "I will use local and I want you to stand by." He did this somewhat reluctantly. Everything went well and I have never done a CEA under general anesthesia since. I am surprised that only 3% of your cases were under local. Gradually our anesthesiologists learned neck block and many of them now prefer it and agree that it is safer than general, with no fluctuation of BP and no post CEA hypertension. In addition we learned that with an awake patient we only need a shunt in about 8% of patients. With an awake patient we could also test the accuracy of both stump pressure and EEG as guides to the need for a shunt. We learned that EEG monitoring is a reliable guide, but results in more shunts than necessary. Then in 1970, Sam Etheredge taught me eversion endarterectomy, which I recently switched to, eliminating the need for patching. I agree that arteriography is rarely necessary now, and discharge is usually the following day. I also believe in leaving a small Penrose in the wound overnight and reversing the heparin to avoid hematomas. When a surgeon can't understand how the recurrent was harmed since he had isolated it, I say "you probably unknowingly clamped the vagus also when you clamped the common carotid!"
In summary, I believe the best defense against the C-stent procedure, will be the results of cases done under local. As long as the patient doesn't have angina or known coronary disease, I have found CEA under local, safe for both symptomatic and nonsymptomatic patients, just as the stenting advocates claim only for their technique.
DR. CHRISTOPHER K. ZARINS (STANFORD, CALIFORNIA): Dr. LaMuraglia, I would like to congratulate you on a superb series and outstanding results. You have performed more than 2000 carotid endarterectomies with a 1.4% stroke death rate. Over the past 10 years at Stanford we have performed more than 1200 patients and also have a 1% combined stroke death rate. So I think in contemporary series these excellent results are achievable not only on the East Coast but also on the West Coast.
However, many do not believe these results because there is no independent neurologic evaluation. How do we address this issue? Carotid stenting has made great inroads because they propose to treat high risk patients. But your series and our series encompass high risk patients, including redo carotid operations. Your experience includes everybody, including the high risk patients, which are currently being studied in high risk carotid stenting trials.
These trials consider the expected results to be like in the NASCET trial, a 5.8% stroke death rate. Current comparative prospective trials for carotid stenting are finding 6 -10% stroke death rates. Many think that is acceptable, and the FDA is now considering approval of carotid stenting with cerebral protection with a 6% stroke death rate. Will this now be the new standard of care?
I notice in your series that two-thirds of your patients were asymptomatic. This is similar in our series and is similar in the high risk clinical trials. Treatment of asymptomatic carotid stenosis is indicated if the stroke death rate is very low, as in your series. However, if you have an asymptomatic patient with a recent MI, maybe you shouldn't touch that carotid rather than treat with a stent and have a 6 -10% stroke death rate.
So how are we going to take the data that you presented here and actually make people think and believe that this indeed is the standard of care for patients with carotid disease, particularly those with asymptomatic carotid disease?
DR. GLENN M. LAMURAGLIA (BOSTON, MASSACHUSETTS): First of all, I would like to thank all the discussants for their good questions.
First to answer the question of the relationship of symptomatic patients and the development of late stroke. When we analyzed both our perioperative and long-term results with reference to stroke and preoperative symptoms, there was essentially no correlation. In fact, in the long term strokes, about 62% of those patients who had them, were asymptomatic patients at the time of their carotid surgery. So we did not find long-term stroke association with either asymptomatic or symptomatic patients.
Relating to the questions of comorbid risk factors and longevity, there have been a number of studies that have tried to answer that question. Some, but not all, of the studies have shown that if you have 2 or 3 major risk factors that you do have a decreased longevity at 5 years by about 50%, compared to patients who have no risk factors. The problem is to be able to conclusively identify which risk factors or comorbidities are of major significance in these carotid patients and how long they may survive. This is still controversial, but coronary artery disease has been commonly identified as a risk factor.
Relating to this, I don't think that there is any data or consensus that is available at this time to identify which patients we should not offer carotid surgery to. This leads to one of Dr. Connolly's questions, how do we decide who to operate on? What we have generally done is tried to identify Annals of Surgery • Volume 240, Number 3, September 2004 Carotid Endarterectomy whether or not we think the patient's likelihood of living 2 years is high or low. Although there are multiple studies that have identified just as good a benefit both in terms of survival and stroke-free survival in octogenarians, we especially want to be sure that these patients have a good cardiac risk stratification. For all patients we also use the clinical criteria that Eagle and others have reported, which are those with known significant coronary disease, history of congestive heart failure, diabetes, renal insufficiency and poor functional status. With those patients, we are much more careful in preoperative cardiac screening.
Relating to the questions on costs of carotid intervention, the costs for these procedures are quite high. A carotid stent alone costs approximately $1200. That does not include the protection device, wires, balloons and all the other materials or the cath lab time. In a study that was published from the New York Hospital, they actually found that there was a significantly higher cost of the percutaneous procedures for carotid artery stenting than for an open-ended endarterectomy. In the study, they created a model to look at their perioperative strokes and other operative complications, and compare carotid surgery with carotid stents. They found that due to the higher incidence of strokes with stents, that it was still not cost effective to undertake a carotid artery stent procedure. They found that the per-patient savings for carotid endarterectomy was in the order of $7000.
In terms of the question relating to heparin and heparin reversal, there have been a few studies that have shown that there is a slightly higher incidence of perioperative stroke or neurologic events with the use of heparin reversal, and we generally do not use it unless there is a strong clinical indication for that.
The questions relating to beta blockade I think are of historical and present interest. I remember in training we couldn't take a patient to the operating room who had a beta blocker because everybody knew, at that time, that beta blocker and general anesthesia were incompatible because the patient would not be able to mount their regular physiologic defenses if they became hypotensive. On the other hand, today we have found the direct opposite of that is important; that actually beta blockade diminishes the perioperative cardiac complications. In fact, one of the methods during our preoperative patient assessment is the administration of a beta blocker unless there is a strict contraindication.
Relating to the question from Dr. Zarins, I am glad to hear that carotid surgery results are as good on the West Coast as they are on the East Coast. I share your concern about people not paying much attention to retrospective results. It is true that these retrospective results do have their limitations. An example is the issue of patient capture: was it at the time of carotid surgery or at the time of intention to treat? We likely missed some patients that may have had a periangiographic stroke that was not included in our database, as was counted in the ACAS study. On the other hand, these studies do not exclude patients as prospective trials do, based on inclusion criteria, and, in that way, better reflect clinical care as it is practiced.
It is also important to point out that some of these large randomized studies comparing best medical treatment to carotid surgery were performed in an era when medical care was quite different. One of the greatest advances that we have had recently is that the perioperative care of the patient, both from a medical and anesthesia perspective. I think this has dramatically improved our surgical results, and the generation of clinical pathways have provided cost savings and standardization of care.
The last question I would like to address relates to "what would I do?" when faced with a patient: carotid endarterectomy of carotid stent. I would like to preface that by saying that our surgical group has taken on percutaneous intervention as part of our regular armamentarium and, in fact, we spend the equivalent of about 20% of our time performing percutaneous procedures. We have not, however, taken on routine carotid artery stenting, since it is still early in its evolution. However, we are interested in this approach and are members of the CREST trial, which we believe will provide many important answers to the role for carotid intervention.
Like so many other new treatments, we have to be cautious and circumspect about routinely using carotid stenting to our patients, especially when our patients do this well with carotid surgery. On the other hand, 20 -30 years ago had carotid artery stenting been available when I was in training, I probably would have embraced it more readily than maybe I would now just because of the greater number of medical problems and issues that patients had with carotid surgery and anesthesia in that era.
I think there will be a role for carotid artery stenting, though I am not quite sure exactly what that role is. I think that an important way to answer the question is to undertake good prospective and retrospective studies. In addition to periprocedural complications, I think better understanding of true long-term results of carotid artery stenting needs to be achieved, since most of the literature really only provides 2-, and at most 3-year follow-up for these patients. This will help identify what role it will or will not have in the treatment of these patients with severe carotid stenosis.
